The estimated Net Worth of Paul Rothman is at least $422 Тысяча dollars as of 6 June 2024. Paul Rothman owns over 717 units of Merck & Co Inc stock worth over $82,247 and over the last 11 years he sold MRK stock worth over $0. In addition, he makes $340,000 as Independent Director at Merck & Co Inc.
Sign up
Paul Rothman MRK stock SEC Form 4 insiders trading
Paul has made over 1 trades of the Merck & Co Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 717 units of MRK stock worth $82,247 on 6 June 2024.
The largest trade he's ever made was exercising 717 units of Merck & Co Inc stock on 6 June 2024 worth over $82,247. On average, Paul trades about 51 units every 0 days since 2014. As of 6 June 2024 he still owns at least 717 units of Merck & Co Inc stock.
You can see the complete history of Paul Rothman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Paul Rothman biography
Dr. Paul B. Rothman is Independent Director of the Company. Dr. Rothman has extensive expertise in patient care, science and medicine relevant to the pharmaceutical industry, including through his positions as the CEO of Johns Hopkins Medicine and the Dean of Medical Faculty and Vice President for Medicine, The Johns Hopkins University, and his past experience as Dean and Head of Internal Medicine at Carver College of Medicine at the University of Iowa. In addition, his vast operational and management experience of a large-scale medical organization provide him with a deep understanding of the complexities of the U.S. healthcare delivery system and policy environment. Johns Hopkins University?Dean of the Medical Faculty and Vice President for Medicine (2012-present) Johns Hopkins Medicine ?Chief Executive Officer (2012-present) Carver College of Medicine at the University of Iowa Dean (2008-2012) ?Head of Internal Medicine (2004-2008).
What is the salary of Paul Rothman?
As the Independent Director of Merck & Co Inc, the total compensation of Paul Rothman at Merck & Co Inc is $340,000. There are 13 executives at Merck & Co Inc getting paid more, with Kenneth Frazier having the highest compensation of $27,648,500.
How old is Paul Rothman?
Paul Rothman is 62, he's been the Independent Director of Merck & Co Inc since 2015. There are 11 older and 15 younger executives at Merck & Co Inc. The oldest executive at Merck & Co Inc is Thomas Cech, 73, who is the Independent Director.
What's Paul Rothman's mailing address?
Paul's mailing address filed with the SEC is 531 SOUTH SPRING STREET, , BURLINGTON, NC, 27215.
Insiders trading at Merck & Co Inc
Over the last 15 years, insiders at Merck & Co Inc have traded over $138,980,380 worth of Merck & Co Inc stock and bought 48,209 units worth $1,563,736 . The most active insiders traders include Wendell P Weeks, Kenneth C Frazier и Douglas M Jr Baker. On average, Merck & Co Inc executives and independent directors trade stock every 15 days with the average trade being worth of $5,050,222. The most recent stock trade was executed by Chirfi Guindo on 5 August 2024, trading 36,901 units of MRK stock currently worth $4,250,995.
What does Merck & Co Inc do?
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.
What does Merck & Co Inc's logo look like?
Complete history of Paul Rothman stock trades at Cancer Genetics, Labcorp и Merck & Co Inc
Merck & Co Inc executives and stock owners
Merck & Co Inc executives and other stock owners filed with the SEC include:
-
Kenneth Frazier,
Chairman of the Board, President, Chief Executive Officer -
Roger Perlmutter,
Executive Vice President, President - Merck Research Laboratories -
Robert Davis,
Executive Vice President, Global Services, Chief Financial Officer -
Sanat Chattopadhyay,
Executive Vice President and President - Merck Manufacturing Division -
Jennifer Zachary,
Executive Vice President, General Counsel, Corporate Secretary -
Kenneth C. Frazier,
Exec. Chairman -
Robert M. Davis,
Pres, CEO & Director -
Jennifer L. Zachary,
Exec. VP, Gen. Counsel & Corp. Sec. -
Sanat Chattopadhyay,
Exec. VP & Pres of Merck Manufacturing Division -
Thomas Cech,
Independent Director -
Leslie Brun,
Lead Independent Director -
Pamela Craig,
Independent Director -
Thomas Glocer,
Independent Director -
Paul Rothman,
Independent Director -
Peter Wendell,
Independent Director -
Inge Thulin,
Independent Director -
Patricia Russo,
Independent Director -
Mary Coe,
Independent Director -
Kathy Warden,
Independent Director -
Christine Seidman,
Independent Director -
Michael Fleming,
Senior Vice President, Chief Ethics and Compliance Officer -
Rita Karachun,
Senior Vice President Finance - Global Controller -
Julie Gerberding,
Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health -
Richard DeLuca,
Executive Vice President, President - Merck Animal Health -
Franklin Clyburn,
Executive Vice President, Chief Commercial Officer -
Michael Nally,
Executive Vice President, Chief Marketing Officer -
Steven Mizell,
Executive Vice President, Chief Human Resources Officer, Human Resources -
Cristal N. Downing,
Exec. VP and Chief Communications & Public Affairs Officer -
Michael W. Fleming,
Sr. VP and Chief Ethics & Compliance Officer -
Peter Dannenbaum,
VP of Investor Relations -
Jennifer Mauer,
VP of Global Communications -
Peter Dannenbaum CFA,
VP of Investor Relations -
David Michael Williams,
Chief Information & Digital Officer -
Caroline Litchfield,
Exec. VP & CFO -
Rochelle B Lazarus,
Director -
Craig B. Thompson,
Director -
Adam H Schechter,
EVP & Pres-Global Human Health -
Adele D Ambrose,
V-P & Chief Com. Officer -
Clark Golestani,
EVP & Chief Info Officer -
John H Noseworthy,
Director -
Wendell P Weeks,
Director -
Michael J Holston,
EVP, Chief Ethics & Compl Ofcr -
Carlos E Represas,
Director -
C Robert Kidder,
Director -
Weir Mirian M Graddick,
Exec. V-P, Human Resources -
Ashley Watson,
SVP Chief Ethics & Com Officer -
Frank Clyburn,
EVP & Pres ? Human Health -
James H Scholefield,
EVP,Chief Info&Digital Officer -
Joseph Romanelli,
President, Human Health Int?l -
Stephen Mayo,
Director -
Dean Y Li,
Executive VP & President, MRL -
David Michael Williams,
EVP,Chief Info&Digital Officer -
William B Jr Harrison,
Director -
Michael Rosenblatt,
Exec V-P & Chief Med Officer -
John Canan,
Senior V-P, Controller -
Stanley F Barshay,
Exec V-P Consumer Health Care -
Willie A Deese,
Exec. V-P and Pres., MMD -
Anne M Tatlock,
Director -
Samuel O Md Thier,
Director -
Mervyn Turner,
Chief Strategy Officer -
Willam N Kelley,
Director -
Richard S Iii Bowles,
Exe V-P & Chief Compl Officer -
Peter S Kim,
Exec. V-P and Pres., MRL -
Thomas E Shenk,
Director -
Bridgette P Heller,
Exe.VP & Pres.Con.Hlth.Care -
Raul E Kohan,
Exe V-P & Pres, Animal Health -
Steven F Goldstone,
Director -
Harry R Jacobson,
Director -
Richard T Clark,
Chairman, President and CEO -
Peter N Kellogg,
Exec. V.P. & C.F.O -
Bruce N Kuhlik,
Exec. V.P. and General Counsel -
Cuong V Do,
EVP & Chief Strategy Officer -
J Chris Scalet,
Exe. VP, Global Services & CIO -
Risa J Lavizzo Mourey,
Director -
Johannes Jacobus Oosthuizen,
President, U.S. Market -
Caroline Litchfield,
EVP & CFO -
Lisa Le Cointe Cephas,
SVP Chief Ethics & Com Officer -
Michael A Klobuchar,
EVP - Chief Strategy Officer -
Arpa Garay,
SVP Human Health Global Mktg. -
Cristal N Downing,
Chief Comm. & Public Afrs Ofcr -
Douglas M Jr Baker,
Director -
Chirfi Guindo,
Chief Marketing Officer -
Dalton Smart,
SVP Fin. - Global Controller -
Betty D Larson,
EVP, Chief HR Officer